Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children

被引：14
|
作者：
Chanthavanich, Pornthep [1 ]
Limkittikul, Kriengsak [1 ]
Sirivichayakul, Chukiat [1 ]
Chokejindachai, Watcharee [1 ]
Hattasingh, Weerawan [1 ]
Pengsaa, Krisana [1 ]
Surangsrirat, Surachai [2 ]
Srisuwannaporn, Termsang [2 ]
Kaewma, Benjawan [2 ]
Yoksan, Sutee [3 ]
Jun, Gao [4 ]
Zhumu, Bai [4 ]
机构：
[1] Mahidol Univ, Fac Trop Med, Dept Trop Pediat, 420-6 Rajvithi Rd, Bangkok 10400, Thailand
[2] Nopparat Rajathanee Hosp, Minist Publ Hlth, Bangkok, Thailand
[3] Mahidol Univ, Inst Mol Biosci, Ctr Vaccine Dev, Japanese Encephalitis Dengue Virol Lab, Bangkok, Thailand
[4] Liaoning Cheng Da Biotechnol Co Ltd, Shenyang, Liaoning, Peoples R China
来源：
HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2018年 / 14卷 / 04期
关键词：
children; chromatographical purify; immunogenicity; Inactivated Vero cell-derived JE vaccine; pediatrics; safety; vaccinology; TRAVELERS;
D O I：
10.1080/21645515.2017.1414763
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Inactivated mouse-brain-derived Japanese encephalitis vaccine has a worrisome safety profile and the live attenuated vaccine is unsuitable in immunodeficiency. This study aimed to evaluate the immunogenicity and safety of an inactivated chromatographically purified Vero-cell-derived JE vaccine (CVI-JE, Beijing P-3 strain) in children. 152 healthy Thai children, with an average (SD) age of 14.4 (3.8) months, received 3 doses of CVI-JE on days 0, 7-28, and one year. Homologous JE neutralizing antibody titers (NT) were measured. All subjects had seroprotection [geometric mean titer (GMT) 150] 28 days' post 2nd vaccination. The seroprotection rates at 1 year after primary series and and 1 month after the booster were 89.3% (GMT 49) and 100% (GMT 621), respectively. Local and systemic reactions-fever (17.6%), vomiting (8%), and poor appetite (5.3%)-were noted within 28 days' post-vaccination. All these symptoms were self-limited. Conclusions: CVI-JE is safe, immunogenic, and provided high NT.
引用
收藏
页码：900 / 905
页数：6
相关论文
共 50 条
  • [21] Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) in children
    Chokephaibulkit, K.
    Houillon, G.
    Feroldi, E.
    Bouckenooghe, A.
    EXPERT REVIEW OF VACCINES, 2016, 15 (02) : 153 - 166
  • [22] Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2012-2016
    Walker, William L.
    Hills, Susan L.
    Miller, Elaine R.
    Fischer, Marc
    Rabe, Ingrid B.
    VACCINE, 2018, 36 (29) : 4369 - 4374
  • [23] Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009-2012
    Rabe, Ingrid B.
    Miller, Elaine R.
    Fischer, Marc
    Hills, Susan L.
    VACCINE, 2015, 33 (05) : 708 - 712
  • [24] Dose-related antibody responses to purified Vero cell rabies vaccine in healthy Thai children
    Chanthavanich, P
    Sabchareon, A
    Singhasivanon, V
    Pojjaroen-Anant, C
    Chongsuphajaisiddhi, T
    Kittikoon, P
    RABIES CONTROL IN ASIA, 1997, : 97 - 100
  • [25] A purified inactivated vaccine derived from Vero cell-adapted zika virus elicits protection in mice
    Oh, Hyun-Seok
    Yoon, Jong Won
    Lee, Sanghyun
    Kim, Soo-Ok
    Hong, Sun Pyo
    VIROLOGY, 2021, 560 : 124 - 130
  • [26] Safety, immunogenicity and antibody persistence of an inactivated hepatitis A vaccine in 4 to 15 year old children
    de Febres, OC
    de Petrola, MC
    de Escalona, LC
    Naveda, O
    Naveda, M
    Estopinan, M
    Bordones, G
    Zambrano, B
    Garcia, A
    Dumas, R
    VACCINE, 1999, 18 (7-8) : 656 - 664
  • [27] Production and evaluation of a chromatographically purified Vero cell rabies vaccine (PVRV) in China using microcarrier technology
    Yu, Pengcheng
    Huang, Ying
    Zhang, Yibin
    Tang, Qing
    Liang, Guodong
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (09) : 1230 - 1235
  • [28] Safety and immunogenicity of a ChAd155-vectored rabies vaccine compared with inactivated, purified chick embryo cell rabies vaccine in healthy adults
    Phadke, Varun K.
    Gromer, Daniel J.
    Rebolledo, Paulina A.
    Graciaa, Daniel S.
    Wiley, Zanthia
    Sherman, Amy C.
    Scherer, Erin M.
    Leary, Maranda
    Girmay, Tigisty
    Mccullough, Michele P.
    Min, Ji-Young
    Capone, Stefania
    Sommella, Andrea
    Vitelli, Alessandra
    Retallick, Jamie
    Seetahal, Janine
    Koller, Mark
    Tsong, Rachel
    Neill-Gubitz, Hannah
    Mulligan, Mark J.
    Rouphael, Nadine G.
    VACCINE, 2024, 42 (26)
  • [29] Evaluation of rabies immunogenicity and tolerability following a purified chick embryo cell rabies vaccine administered concomitantly with a Japanese encephalitis vaccine
    Jelinek, Tomas
    Cramer, Jakob P.
    Dieckmann, Sebastian
    Hatz, Christoph
    Paulke-Korinek, Maria
    Alberer, Martin
    Reisinger, Emil C.
    Costantini, Marco
    Gniel, Dieter
    Bosse, Dietrich
    Lattanzi, Maria
    TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2015, 13 (03) : 241 - 250
  • [30] Safety and Immunogenicity of an Inactivated Quadrivalent Influenza Vaccine in Children 6 Months through 8 Years of Age
    Greenberg, David P.
    Robertson, Corwin A.
    Landolfi, Victoria A.
    Bhaumik, Amitabha
    Senders, Shelly D.
    Decker, Michael D.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2014, 33 (06) : 630 - 636
12345